LOS ANGELES, CA--(Marketwire - November 09, 2009) -
| Highlighted Links |
HemaCare Web site |
Gross profit from continuing operations decreased $58,000, or 4%, in the quarter to $1.5 million, primarily driven by an 11% decrease in revenue compared to prior year, attributable to a 17% decrease in blood products revenue. This was the result of increased competition caused by an unprecedented excess supply of blood products in the United States due to the recent downturn in the economy. Gross profit margin from continuing operations in the quarter was 17%, compared to 16% in the third quarter of 2008.
Commenting on the results, John Doumitt, the Company's Chief Executive Officer, stated, "While this was a challenging revenue quarter for the Company, we are pleased to have maintained profitability and are gratified that we were able to recently add new customers who recognize the important value we provide."
HemaCare Corporation
Condensed Consolidated Data
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
Statements of Income: 2009 2008 2009 2008
----------- ----------- ----------- ------------
Revenue $ 8,401,000 $ 9,474,000 $28,140,000 $ 27,642,000
Gross profit $ 1,453,000 $ 1,511,000 $ 5,027,000 $ 4,797,000
General and
administrative
expenses $ 1,295,000 $ 1,452,000 $ 4,368,000 $ 4,375,000
----------- ----------- ----------- ------------
Income from operations $ 158,000 $ 59,000 $ 659,000 $ 422,000
Other income $ - $ 396,000 $ - $ 331,000
----------- ----------- ----------- ------------
Income before income
taxes and discontinued
operations $ 158,000 $ 455,000 $ 659,000 $ 753,000
(Benefit from)
provision for income
taxes $ (88,000) $ - $ (38,000) $ 45,000
----------- ----------- ----------- ------------
Income from continuing
operations $ 246,000 $ 455,000 $ 697,000 $ 708,000
----------- ----------- ----------- ------------
(Loss) income from
discontinued
operations, net of tax
impact $ (13,000) $ (170,000) $ (37,000) $ 92,000
----------- ----------- ----------- ------------
Net income $ 233,000 $ 285,000 $ 660,000 $ 800,000
=========== =========== =========== ============
Basic earnings per
share $ 0.02 $ 0.03 $ 0.07 $ 0.08
=========== =========== =========== ============
Diluted earnings per
share $ 0.02 $ 0.03 $ 0.07 $ 0.08
=========== =========== =========== ============
Weighted average shares
outstanding - basic 10,050,000 9,696,000 9,994,000 9,415,000
=========== =========== =========== ============
Weighted average shares
outstanding - diluted 10,257,000 9,942,000 10,086,000 9,415,000
=========== =========== =========== ============
Balance Sheets: September 30, December 31,
2009 2008
----------- -----------
Assets
Cash and cash
equivalents $ 1,325,000 $ 903,000
Other current assets 6,157,000 8,298,000
Non-current assets 4,292,000 4,495,000
----------- -----------
Total assets $11,774,000 $13,696,000
=========== ===========
Liabilities and
Shareholders' Equity
Current liabilities $ 5,809,000 $ 8,513,000
Long-term liabilities 659,000 645,000
Shareholders' equity 5,306,000 4,538,000
----------- -----------
Total liabilities and
shareholders' equity $11,774,000 $13,696,000
=========== ===========
Contact:
HemaCare Corporation
Robert S. Chilton
Executive Vice President and Chief Financial Officer
877-310-0717
www.hemacare.com